New hope for myeloma patients: testing a powerful drug duo

NCT ID NCT07280013

Recruiting now Disease control Sponsor: C4 Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing the safety of a new two-drug combination for people with multiple myeloma that has come back or stopped responding to other treatments. About 60 participants will take a pill (cemsidomide) and receive an injection (elranatamab) to see how well they are tolerated together. The main goal is to find a safe dose and check for early signs that the treatment might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Banner MD Anderson Cancer Center
NOT_YET_RECRUITING

Gilbert, Arizona, 85234, United States
Dartmouth-Hitchcock Medical Center
NOT_YET_RECRUITING

Lebanon, New Hampshire, 03756, United States
Duke Cancer Center
NOT_YET_RECRUITING

Durham, North Carolina, 27710, United States
Houston Methodist Hospital
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Huntsman Cancer Institute, University of Utah
NOT_YET_RECRUITING

Salt Lake City, Utah, 84112, United States
Indiana University
NOT_YET_RECRUITING

Indianapolis, Indiana, 46202, United States
Loyola University Medical Center
NOT_YET_RECRUITING

Maywood, Illinois, 60153, United States
MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Medical College of Wisconsin
NOT_YET_RECRUITING

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10021, United States
Norton Cancer Institute St. Matthews
NOT_YET_RECRUITING

Louisville, Kentucky, 40207, United States
Oregon Health & Science University
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
Perlmutter Cancer Center at NYU Langone Hospital
NOT_YET_RECRUITING

Brooklyn, New York, 11203, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Tampa General Hospital
NOT_YET_RECRUITING

Tampa, Florida, 33606, United States
UCLA Health, Jonsson Comprehensive Cancer Center
NOT_YET_RECRUITING

Santa Monica, California, 90404, United States
University of Maryland Greenbaum Comprehensive Cancer Center
NOT_YET_RECRUITING

Baltimore, Maryland, 21201, United States
University of Nebraska
NOT_YET_RECRUITING

Omaha, Nebraska, 68105, United States
Winship Cancer Institute, Emory University
NOT_YET_RECRUITING

Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA (MM)